
Cancer drugs central to treatment for for cancer . Today, oncologists use chemotherapy, targeted therapy, and immunotherapy, to treat cancer based on each patient’s disease condition.
Advances in medical science have expanded the range of available cancer drugs, allowing treatment to be precisely tailored according to the cancer type, stage of cancer, and the patient’s overall health.
This guide explains the “ABCs” or basics of cancer drugs, how they function, and how they are selected as part of cancer care today.
Cancer drugs are medications used to treat cancer by killing cancer cells, slowing their growth, or preventing them from spreading. Cancer drugs may be used:
Modern oncology increasingly relies on understanding the biological characteristics of each tumour. This allows doctors to select the most appropriate class of cancer drugs for each patient.

Chemotherapy is one of the most established forms of anti-cancer drugs.
Chemotherapy targets rapidly dividing cells. Since cancer cells divide more quickly than most normal cells, they are particularly sensitive to these medications.
However, some healthy cells that divide quickly, such as those in hair follicles, the digestive tract and bone marrow may also be affected during chemotherapy treatment. This can cause side effects such as hair loss, nausea, loss of appetite and risk of infection.
Chemotherapy may be used:
Because chemotherapy affects rapidly dividing cells, side effects may include:
These side effects are closely monitored by the care team and are usually temporary.
Targeted therapy are cancer drugs that more precisely target the specific type of cancer cells.
Unlike chemotherapy, which broadly affects rapidly dividing cells , targeted therapy focuses on specific molecular changes within cancer cells.
Cancer cells often carry abnormal proteins or genetic mutations that drive growth. Targeted drugs are designed to block these specific pathways.
Examples include the following:
In patients whose breast cancer overexpresses the Human Epidermal Growth Factor 2 (HER2) receptor targeted therapy such as trastuzumab may be used. This cancer drug binds to HER2 receptors on cancer cells and is often given together with chemotherapy.
For example, a patient diagnosed with early-stage HER2-positive breast cancer may receive trastuzumab after surgery to reduce the risk of recurrence. In more advanced cases, it may be combined with other targeted or chemotherapy drugs as part of a structured treatment plan.
In CML, the target is tyrosine kinase, which is the protein produced by the BCR-ABL mutated gene. Target therapy drugs called tyrosine kinase inhibators such as Imatinib block the BCR-ABL protein and are commonly prescribed as long-term oral therapy.
A patient newly diagnosed with CML may be prescribed daily oral imatinib after genetic testing confirms the mutation. Regular blood monitoring helps cancer doctors assess the response and adjust treatment if necessary.
For certain advanced melanomas, immunotherapy drugs such as pembrolizumab may be recommended. These cancer drugs help the immune system recognise and attack cancer cells more effectively.
For instance, when surgery alone is not sufficient to treat metastatic melanoma, the patient may receive immunotherapy as the primary treatment. Treatment response is monitored through imaging and clinical assessment over time.
EGFR mutation lung cancer is driven by mutations in the Epidermal Growth Factor Receptor gene. Patients with this type of lung cancer may receive EGFR inhibitors such as osimertinibafter molecular testing confirms the mutation.
In real-world settings, a patient diagnosed with advanced non-small cell lung cancer may undergo tumour genetic testing. If an EGFR mutation is identified, a targeted oral cancer drug may be prescribed instead of conventional chemotherapy.
Targeted therapy may:
However, not all cancers have identifiable targets, and drug resistance may develop over time.
Side effects vary depending on the pathway targeted and may include skin changes, diarrhoea or liver function abnormalities.

Immunotherapy is a novel type of therapy that works differently from chemotherapy and targeted therapy.
Immunotherapy stimulates or activates the body’s own immune system to recognise and attack cancer cells.
Normally, cancer cells can evade immune detection. Immunotherapy drugs help to remove this “shield,” allowing immune cells to identify, target and attack thecancer cells more effectively.
Checkpoint inhibitors are one example of immunotherapy.
Immunotherapy may be used to treat cancers, including:
However, effectiveness depends on the tumour characteristics and immune markers.
Because immunotherapy activates the immune system, side effects that may result from immune overactivity include :
These side effects are closely monitored and managed by the cancer doctor.
Some cancers are driven by hormones.
Hormonal therapy is a category of cancer drugs used in cancers such as:
These drugs work by:
Side effects may include hot flushes, mood changes, bone thinning or sexual health changes.
In many cases, more than one class of cancer drug is used together.
Combination therapy may:
The sequence of treatment using combination therapy is carefully planned by the cancer doctor.
Selecting the appropriate cancer drug for a patient depends on several factors:
Personalised medicine plays an increasingly important role, with molecular testing of tumour tissue helping to guide treatment decisions.
Patients receiving cancer drugs undergo regular monitoring to assess:
This ensures safety and efficacy of treatment and allows the treating doctor to make adjustments when necessary.
Cancer drugs may be prescribed to achieve different treatment goals:
Discussion with your care team helps to align treatment decisions with the treatment goals.
Each category of cancer drugs can cause different side effects . Supportive care to manage side effects for patients receiving cancer drugs may include:
Close monitoring by the care team allows prompt intervention if the patient experiences side effects.
Research continues to expand the range of available cancer drugs. New developments include:
Ongoing clinical trials contribute to advancing cancer treatment options.
Cancer treatment involves multi-disciplinary planning from the care team which includes :
This team-based approach ensures that cancer drugs prescribed are safe and effective.
If you have questions about your treatment plan, speak with your NCCS care team for personalised guidance.